300 related articles for article (PubMed ID: 28264791)
1. More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments.
Kandolf Sekulovic L; Peris K; Hauschild A; Stratigos A; Grob JJ; Nathan P; Dummer R; Forsea AM; Hoeller C; Gogas H; Demidov L; Lebbe C; Blank C; Olah J; Bastholt L; Herceg D; Neyns B; Vieira R; Hansson J; Rutkowski P; Krajsova I; Bylaite-Bucinskiene M; Zalaudek I; Maric-Brozic J; Babovic N; Banjin M; Putnik K; Weinlich G; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Kukushkina M; De La Cruz Merino L; Ymeri A; Risteski M; Garbe C
Eur J Cancer; 2017 Apr; 75():313-322. PubMed ID: 28264791
[TBL] [Abstract][Full Text] [Related]
2. Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.
Kandolf Sekulovic L; Guo J; Agarwala S; Hauschild A; McArthur G; Cinat G; Wainstein A; Caglevic C; Lorigan P; Gogas H; Alvarez M; Duncombe R; Lebbe C; Peris K; Rutkowski P; Stratigos A; Forsea AM; De La Cruz Merino L; Kukushkina M; Dummer R; Hoeller C; Gorry C; Bastholt L; Herceg D; Neyns B; Vieira R; Arenberger P; Bylaite-Bucinskiene M; Babovic N; Banjin M; Putnik K; Todorovic V; Kirov K; Ocvirk J; Zhukavets A; Ymeri A; Stojkovski I; Garbe C
Eur J Cancer; 2018 Nov; 104():201-209. PubMed ID: 30388700
[TBL] [Abstract][Full Text] [Related]
3. Access to biologicals in Crohn's disease in ten European countries.
Péntek M; Lakatos PL; Oorsprong T; Gulácsi L; Pavlova M; Groot W; Rencz F; Brodszky V; Baji P; Crohn's Disease Research Group
World J Gastroenterol; 2017 Sep; 23(34):6294-6305. PubMed ID: 28974896
[TBL] [Abstract][Full Text] [Related]
4. ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe.
Cherny N; Sullivan R; Torode J; Saar M; Eniu A
Ann Oncol; 2016 Aug; 27(8):1423-43. PubMed ID: 27457309
[TBL] [Abstract][Full Text] [Related]
5. Melanoma prognosis in Europe: far from equal.
Forsea AM; Del Marmol V; Stratigos A; Geller AC
Br J Dermatol; 2014 Jul; 171(1):179-82. PubMed ID: 24588115
[TBL] [Abstract][Full Text] [Related]
6. Survival of patients with melanoma brain metastasis treated with stereotactic radiosurgery and active systemic drug therapies.
Choong ES; Lo S; Drummond M; Fogarty GB; Menzies AM; Guminski A; Shivalingam B; Clarke K; Long GV; Hong AM
Eur J Cancer; 2017 Apr; 75():169-178. PubMed ID: 28236768
[TBL] [Abstract][Full Text] [Related]
7. [Management of patients with metastatic cutaneous melanoma: French national guidelines. French National Cancer Institute].
Leccia MT; Planchamp F; Sassolas B; Combemale P; Modiano P; Bedane C; Cupissol D; Derrey S; Dygai-Cochet I; Lamant L; Lubrano V; Mirabel X; Mourrégot A; Rougé Bugat ME; Siegrist S; Thariat J; Tiffet O; Truc G; Verdoni L; Mazeau-Woynar V
Ann Dermatol Venereol; 2014 Feb; 141(2):111-21. PubMed ID: 24507205
[TBL] [Abstract][Full Text] [Related]
8. Estimating healthcare resource use associated with the treatment of metastatic melanoma in eight countries.
McKendrick J; Gijsen M; Quinn C; Barber B; Zhao Z
J Med Econ; 2016 Jun; 19(6):587-95. PubMed ID: 26823114
[TBL] [Abstract][Full Text] [Related]
9. Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.
Kandel M; Allayous C; Dalle S; Mortier L; Dalac S; Dutriaux C; Leccia MT; Guillot B; Saiag P; Lacour JP; Legoupil D; Lesimple T; Aubin F; Beylot-Barry M; Brunet-Possenti F; Arnault JP; Granel-Brocard F; Stoebner PE; Dupuy A; Maubec E; Grob JJ; Dreno B; Rotolo F; Ballon A; Michiels S; Lebbe C; Borget I
Eur J Cancer; 2018 Dec; 105():33-40. PubMed ID: 30384014
[TBL] [Abstract][Full Text] [Related]
10. [New treatments for metastatic melanoma: a first hope].
Robert C; Mateus C
Rev Prat; 2011 Nov; 61(9 Suppl):S1-2. PubMed ID: 22338196
[No Abstract] [Full Text] [Related]
11. Inequalities in medicine use in Central Eastern Europe: an empirical investigation of socioeconomic determinants in eight countries.
Vogler S; Österle A; Mayer S
Int J Equity Health; 2015 Nov; 14():124. PubMed ID: 26541292
[TBL] [Abstract][Full Text] [Related]
12. [Not Available].
Mateus C; Libenciuc C; Robert C
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S4-S11. PubMed ID: 27494973
[TBL] [Abstract][Full Text] [Related]
13. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
[TBL] [Abstract][Full Text] [Related]
14. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial.
Grob JJ; Amonkar MM; Karaszewska B; Schachter J; Dummer R; Mackiewicz A; Stroyakovskiy D; Drucis K; Grange F; Chiarion-Sileni V; Rutkowski P; Lichinitser M; Levchenko E; Wolter P; Hauschild A; Long GV; Nathan P; Ribas A; Flaherty K; Sun P; Legos JJ; McDowell DO; Mookerjee B; Schadendorf D; Robert C
Lancet Oncol; 2015 Oct; 16(13):1389-98. PubMed ID: 26433819
[TBL] [Abstract][Full Text] [Related]
15. Cost-of-illness of melanoma in Europe - a modelling approach.
Krensel M; Schäfer I; Augustin M
J Eur Acad Dermatol Venereol; 2019 Mar; 33 Suppl 2():34-45. PubMed ID: 30811699
[TBL] [Abstract][Full Text] [Related]
16. Inequities in access to biologic and synthetic DMARDs across 46 European countries.
Putrik P; Ramiro S; Kvien TK; Sokka T; Pavlova M; Uhlig T; Boonen A;
Ann Rheum Dis; 2014 Jan; 73(1):198-206. PubMed ID: 23467636
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study).
Johnston K; Levy AR; Lorigan P; Maio M; Lebbe C; Middleton M; Testori A; Bédane C; Konto C; Dueymes A; Sbarigia U; van Baardewijk M
Eur J Cancer; 2012 Sep; 48(14):2175-82. PubMed ID: 22480965
[TBL] [Abstract][Full Text] [Related]
18. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: A network meta-analysis.
Pasquali S; Chiarion-Sileni V; Rossi CR; Mocellin S
Cancer Treat Rev; 2017 Mar; 54():34-42. PubMed ID: 28189914
[TBL] [Abstract][Full Text] [Related]
20. The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV-UEMS and EORTC Cutaneous Lymphoma Task Force.
Garbe C; Peris K; Soura E; Forsea AM; Hauschild A; Arenbergerova M; Bylaite M; Del Marmol V; Bataille V; Samimi M; Gandini S; Saiag P; Eigentler TK; Lallas A; Zalaudek I; Lebbe C; Grob JJ; Hoeller C; Robert C; Dréno B; Arenberger P; Kandolf-Sekulovic L; Kaufmann R; Malvehy J; Puig S; Leiter U; Ribero S; Papadavid E; Quaglino P; Bagot M; John SM; Richard MA; Trakatelli M; Salavastru C; Borradori L; Marinovic B; Enk A; Pincelli C; Ioannides D; Paul C; Stratigos AJ
J Eur Acad Dermatol Venereol; 2020 Oct; 34(10):2183-2197. PubMed ID: 32840022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
